scPharmaceuticals Inc
SCPH5.670USD
0.000
Close 12/22, 16:00（ET）Quotes delayed by 15 min
302.16MMarket Cap
LossP/E TTM
More Details of scPharmaceuticals Inc Company
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
scPharmaceuticals Inc Info
Ticker SymbolSCPH
Company namescPharmaceuticals Inc
IPO dateNov 17, 2017
CEOMr. John H. Tucker
Number of employees162
Security typeOrdinary Share
Fiscal year-endNov 17
Address25 Burlington Mall Road, Suite 203
CityBURLINGTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code01803
Phone16175170730
Websitehttps://www.scpharmaceuticals.com/
Ticker SymbolSCPH
IPO dateNov 17, 2017
CEOMr. John H. Tucker
Company Executives of scPharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Nov 26
Updated: Wed, Nov 26
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
9.50%
Weiss Asset Management
5.37%
Lundbeckfond Invest
5.34%
The Vanguard Group, Inc.
4.06%
Other
64.45%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
9.50%
Weiss Asset Management
5.37%
Lundbeckfond Invest
5.34%
The Vanguard Group, Inc.
4.06%
Other
64.45%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.71%
Investment Advisor
22.81%
Private Equity
12.37%
Investment Advisor/Hedge Fund
11.59%
Research Firm
4.68%
Bank and Trust
0.38%
Individual Investor
0.36%
Venture Capital
0.12%
Insurance Company
0.03%
Other
17.94%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
203
37.70M
70.24%
-12.04M
2025Q2
207
43.86M
83.06%
-9.87M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
2023Q2
160
30.81M
85.97%
-2.10M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
6.06M
11.29%
--
--
Jun 30, 2025
Rubric Capital Management LP
4.60M
8.57%
-173.02K
-3.62%
Jun 30, 2025
Lundbeckfond Invest
2.86M
5.34%
+2.86M
--
Sep 30, 2024
The Vanguard Group, Inc.
1.84M
3.42%
-157.11K
-7.88%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.99M
3.7%
-164.72K
-7.65%
Jun 30, 2025
Luther King Capital Management Corp.
3.54M
6.6%
+420.00K
+13.46%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.66M
3.1%
+13.12K
+0.80%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 3000 ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Russell 2000 Growth ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
View more
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of scPharmaceuticals Inc?
The top five shareholders of scPharmaceuticals Inc are:
OrbiMed Advisors, LLC holds 6.06M shares, accounting for 11.29% of the total shares.
Rubric Capital Management LP holds 4.60M shares, accounting for 8.57% of the total shares.
Lundbeckfond Invest holds 2.86M shares, accounting for 5.34% of the total shares.
The Vanguard Group, Inc. holds 1.84M shares, accounting for 3.42% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.99M shares, accounting for 3.70% of the total shares.
OrbiMed Advisors, LLC holds 6.06M shares, accounting for 11.29% of the total shares.
Rubric Capital Management LP holds 4.60M shares, accounting for 8.57% of the total shares.
Lundbeckfond Invest holds 2.86M shares, accounting for 5.34% of the total shares.
The Vanguard Group, Inc. holds 1.84M shares, accounting for 3.42% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.99M shares, accounting for 3.70% of the total shares.
What are the top three shareholder types of scPharmaceuticals Inc?
The top three shareholder types of scPharmaceuticals Inc are:
OrbiMed Advisors, LLC
Rubric Capital Management LP
Weiss Asset Management
OrbiMed Advisors, LLC
Rubric Capital Management LP
Weiss Asset Management
How many institutions hold shares of scPharmaceuticals Inc (SCPH)?
As of 2025Q3, 203 institutions hold shares of scPharmaceuticals Inc, with a combined market value of approximately 37.70M, accounting for 70.24% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -12.83%.
What is the biggest source of revenue for scPharmaceuticals Inc?
In --, the -- business generated the highest revenue for scPharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
